Clinical Scenario of a 32-Year-Old Female with AYA ALL and the Role of Cytogenetics in AYA ALL

EP: 1.Clinical Scenario: A 23-Year-Old Male with AYA ALL

EP: 2.AYA ALL: Overview and Risk Stratification

EP: 3.AYA ALL: Pediatric and Adult Inspired Regimens

EP: 4.AYA ALL: Role of Asparaginase Erwinia Chrysanthemi

EP: 5.Asparaginase Erwinia Chrysanthemi: Side Effects and Hypersensitivity Reactions

EP: 6.ALL AYA: Coordination of Care

Now Viewing

EP: 7.Clinical Scenario of a 32-Year-Old Female with AYA ALL and the Role of Cytogenetics in AYA ALL

EP: 8.CALBG 10403 in AYA ALL

EP: 9.The Potential of Modified Treatment Regimens in AYA ALL

EP: 10.The Future of AYA ALL

Video content above is prompted by the following:

• A 32-year-old female with a history of migraines and anxiety presented to the Emergency Department with a one-month history of fatigue and weakness and a two-day history of spontaneous bruising.
• The patient had been undergoing an outpatient workup for anemia with her primary care physician.
• In the ED, blood counts were noted to be abnormal. White blood cell count was 2.9k with neutrophils 8% and lymphocytes 89%, hemoglobin 4.2 g/dL, and platelet count 6k.
• Bone marrow examination revealed cellularity of 100% with 80% blasts expressing CD19, CD10, CD34, HLA-DR, CD38, CD43, CD22, and CD24. FISH and PCR for the BCR-ABL translocation were negative.
  • No Ph-like abnormalities were detected.
  • No malignant cells were identified in the cerebrospinal fluid.
• The patient was initiated on treatment per CALGB 10403.